18 December 2024NewsAmericasRajiv Nayar, President, HTD Biosystems | Chuck Sholtz, Vice President, Intellectual Property, Nutcracker Therapeutics | Benjamin Pelletier, Partner, Haynes & Boone

WATCH: What are the latest challenges in patenting biologics, biosimilars, and bispecific antibodies?

Speakers from HTD Biosystems, Nutcracker Therapeutics, and Haynes & Boone examine the evolving patent landscape for biologics, biosimilars, and bispecific antibodies, sharing practical strategies and jurisdiction-specific insights.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Americas

Penile implant maker’s $17m trade secret award unravels

20 April 2026 The maker of a cosmetic penile implant has suffered at the Federal Circuit, after a ruling said its trade secrets claims are not protectable while leaving a counterfeiting finding intact.

Americas

Appeals court eases Teva’s headache with reversal

17 April 2026 A ruling that invalidated three of Teva's headache treatment patents has been thrown out, sending a long-running case back to the lower court.

Americas

Cancer drug researcher hit with suit over mutation-targeting tools

16 April 2026 The Cambridge biotech is accused of infringing six patents covering technologies used to target drug-resistant cancer mutations.